There is growing interest in using antibodies as auxiliary tools to crystallize proteins. Here we describe a general protocol for the generation of Nanobodies to be used as crystallization chaperones for the structural investigation of diverse conformational states of flexible (membrane) proteins and complexes thereof. Our technology has a competitive advantage over other recombinant crystallization chaperones in that we fully exploit the natural humoral response against native antigens. Accordingly, we provide detailed protocols for the immunization with native proteins and for the selection by phage display of in vivo–matured Nanobodies that bind conformational epitopes of functional proteins. Three representative examples illustrate that the outlined procedures are robust, making it possible to solve by Nanobody-assisted X-ray crystallography in a time span of 6–12 months.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Studying the characteristics of nanobody CDR regions based on sequence analysis in combination with 3D structures
Journal of Genetic Engineering and Biotechnology Open Access 21 November 2022
Fluids and Barriers of the CNS Open Access 03 October 2022
Nature Communications Open Access 17 August 2022
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rasmussen, S.G. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175–180 (2011).
Rasmussen, S.G. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011).
Low, C. et al. Nanobody mediated crystallization of an archeal mechanosensitive channel. PLoS ONE 8, e77984 (2013).
Baranova, E. et al. SbsB structure and lattice reconstruction unveil Ca2+ triggered S-layer assembly. Nature 487, 119–122 (2012).
Park, Y.J., Pardon, E., Wu, M., Steyaert, J. & Hol, W.G. Crystal structure of a heterodimer of editosome interaction proteins in complex with two copies of a cross-reacting nanobody. Nucleic Acids Res. 40, 1828–1840 (2012).
Korotkov, K.V. et al. Structural and functional studies on the interaction of GspC and GspD in the type II secretion system. PLoS Pathog. 7, e1002228 (2011).
Loris, R. et al. Crystal structure of the intrinsically flexible addiction antidote MazE. J. Biol. Chem. 278, 28252–28257 (2003).
Abskharon, R.N. et al. Combining in situ proteolysis and microseed matrix screening to promote crystallization of PrPc-nanobody complexes. Protein Eng. Des. Sel. 24, 737–741 (2011).
Domanska, K. et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β2-microglobulin variant. Proc. Natl. Acad. Sci. USA 108, 1314–1319 (2011).
Guilliams, T. et al. Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. J. Mol. Biol. 425, 2397–2411 (2013).
Muyldermans, S., Cambillau, C. & Wyns, L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 26, 230–235 (2001).
Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).
Lauwereys, M. et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 17, 3512–3520 (1998).
De Genst, E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. USA 103, 4586–4591 (2006).
Newby, Z.E. et al. A general protocol for the crystallization of membrane proteins for X-ray structural investigation. Nat. Protoc. 4, 619–637 (2009).
Koch-Nolte, F. et al. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J. 21, 3490–3498 (2007).
Laeremans, T. et al. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4. WO patent 2,010,070,145 (2010).
Roovers, R.C. et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol. Immunother. 56, 303–317 (2007).
Desmyter, A. et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3, 803–811 (1996).
Decanniere, K. et al. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7, 361–370 (1999).
Desmyter, A. et al. Three camelid VHH domains in complex with porcine pancreatic α-amylase. Inhibition and versatility of binding topology. J. Biol. Chem. 277, 23645–23650 (2002).
Dumoulin, M. et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424, 783–788 (2003).
Korotkov, K.V., Pardon, E., Steyaert, J. & Hol, W.G. Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure 17, 255–265 (2009).
Park, Y.J. et al. The structure of the C-terminal domain of the largest editosome interaction protein and its role in promoting RNA binding by RNA-editing ligase L2. Nucleic Acids Res. 40, 6966–6977 (2012).
Vanderhaegen, S. et al. Structure of an early native-like intermediate of β2-microglobulin amyloidogenesis. Protein Sci. 22, 1349–1357 (2013).
Ward, A.B. et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc. Natl. Acad. Sci. USA 110, 13386–13391 (2013).
Banner, D.W. et al. Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr. D Biol. Crystallogr. 69, 1124–1137 (2013).
Tereshko, V. et al. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci. 17, 1175–1187 (2008).
Spinelli, S. et al. Lactococcal bacteriophage p2 receptor-binding protein structure suggests a common ancestor gene with bacterial and mammalian viruses. Nat. Struct. Mol. Biol. 13, 85–89 (2006).
Wu, M. et al. Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies. J. Struct. Biol. 174, 124–136 (2011).
Koide, S. Engineering of recombinant crystallization chaperones. Curr. Opin. Struct. Biol. 19, 449–457 (2009).
Bukowska, M.A. & Grutter, M.G. New concepts and aids to facilitate crystallization. Curr. Opin. Struct. Biol. 23, 409–416 (2013).
Steyaert, J. & Kobilka, B.K. Nanobody stabilization of G protein-coupled receptor conformational states. Curr. Opin. Struct. Biol. 21, 567–572 (2011).
Westfield, G.H. et al. Structural flexibility of the Gαs α-helical domain in the β2-adrenoceptor Gs complex. Proc. Natl. Acad. Sci. USA 108, 16086–16091 (2011).
Rivera-Calzada, A. et al. Structure of a bacterial type IV secretion core complex at subnanometre resolution. EMBO J. 32, 1195–1204 (2013).
Vercruysse, T. et al. Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biol. 8, 316–324 (2011).
Rothbauer, U. et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods 3, 887–889 (2006).
Irannejad, R. et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 495, 534–538 (2013).
Vercruysse, T., Pardon, E., Vanstreels, E., Steyaert, J. & Daelemans, D. An intrabody based on a llama single-domain antibody targeting the N-terminal α-helical multimerization domain of HIV-1 rev prevents viral production. J. Biol. Chem. 285, 21768–21780 (2010).
Lawson, A.D. Antibody-enabled small-molecule drug discovery. Nat. Rev. Drug Discov. 11, 519–525 (2012).
Structural Genomics Consortium. et al. Protein production and purification. Nat. Methods 5, 135–146 (2008).
Vedadi, M., Arrowsmith, C.H., Allali-Hassani, A., Senisterra, G. & Wasney, G.A. Biophysical characterization of recombinant proteins: a key to higher structural genomics success. J. Struct. Biol. 172, 107–119 (2010).
Jahnichen, S. et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. USA 107, 20565–20570 (2010).
Paalanen, M.M. et al. The development of activating and inhibiting camelid VHH domains against human protein kinase Cɛ. Eur. J. Pharm. Sci. 42, 332–339 (2011).
Lee, G.M. & Craik, C.S. Trapping moving targets with small molecules. Science 324, 213–215 (2009).
Flajnik, M.F., Deschacht, N. & Muyldermans, S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol. 9, e1001120 (2011).
De Genst, E., Saerens, D., Muyldermans, S. & Conrath, K. Antibody repertoire development in camelids. Dev. Comp. Immunol. 30, 187–198 (2006).
Conrath, K.E. et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45, 2807–2812 (2001).
van der Linden, R. et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J. Immunol. Methods 240, 185–195 (2000).
Maass, D.R., Sepulveda, J., Pernthaner, A. & Shoemaker, C.B. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods 324, 13–25 (2007).
Kastelic, D. et al. A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J. Immunol. Methods 350, 54–62 (2009).
Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105–1116 (2005).
Koide, A. & Koide, S. Affinity maturation of single-domain antibodies by yeast surface display. in Single-Domain Antibodies 431–443 (Springer, 2012).
Ryckaert, S., Pardon, E., Steyaert, J. & Callewaert, N. Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. J. Biotechnol. 145, 93–98 (2010).
Fleetwood, F. et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell Mol. Life Sci. 70, 1081–1093 (2013).
Nizak, C., Moutel, S., Goud, B. & Perez, F. Selection and application of recombinant antibodies as sensors of Rab protein conformation. Methods Enzymol. 403, 135–153 (2005).
Verheesen, P. & Laeremans, T. Selection by phage display of single-domain antibodies specific to antigens in their native conformation. in Single-Domain Antibodies 81–104 (Springer, 2012).
Muyldermans, S. Single-domain camel antibodies: current status. J. Biotechnol. 74, 277–302 (2001).
Zell, R. & Fritz, H.J. DNA mismatch-repair in Escherichia coli counteracting the hydrolytic deamination of 5-methyl-cytosine residues. EMBO J. 6, 1809–1815 (1987).
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R. & Muyldermans, S. Selection and identification of single-domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414, 521–526 (1997).
De Genst, E.J. et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J. Mol. Biol. 402, 326–343 (2010).
Deng, J. et al. An improved protocol for rapid freezing of protein samples for long-term storage. Acta Crystallogr. D Biol. Crystallogr. 60, 203–204 (2004).
Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446–448 (1993).
Daley, L.P., Gagliardo, L.F., Duffy, M.S., Smith, M.C. & Appleton, J.A. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids. Clin. Diagn. Lab. Immunol. 12, 380–386 (2005).
Chomczynski, P. & Sacchi, N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 1, 581–585 (2006).
Esterhazy, D. et al. Bace2 is a beta cell–enriched protease that regulates pancreatic beta cell function and mass. Cell Metab. 14, 365–377 (2011).
Kobilka, B.K. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein–coupled receptor. Anal. Biochem. 231, 269–271 (1995).
Chae, P.S. et al. Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat. Methods 7, 1003–1008 (2010).
Whorton, M.R. et al. A monomeric G protein–coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. USA 104, 7682–7687 (2007).
Lam, A.Y., Pardon, E., Korotkov, K.V., Hol, W.G. & Steyaert, J. Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J. Struct. Biol. 166, 8–15 (2009).
Gonzalez Pajuelo, M., Hermans, G. & Vanlandschoot, P. Panning phage libraries with lipoprotein particles expressing the target antigen. WO patent 2,011,083,141 (2011).
Bich, C. et al. Reactivity and applications of new amine reactive cross-linkers for mass spectrometric detection of protein-protein complexes. Anal. Chem. 82, 172–179 (2010).
We thank members and associates of the Steyaert, Muyldermans, Hol and Kobilka laboratories, past and present, for their assorted contributions over the years to this work. In particular, we acknowledge the contributions of N. Buys and Y.J. Park. The Steyaert laboratory was supported by the Fonds Wetenschappelijk Onderzoek-Vlaanderen through research grants G011110N and G049512N, Innoviris Brussels through the Impulse Life Science program BRGEOZ132, the Belgian Federal Science Policy Office through IAP7-40 and by the SBO program IWT120026 from the Flemish Agency for Innovation by Science and Technology. B.K.K. received support from US National Institutes of Health (NIH) grants R01NS028471 and R01GM083118 and from the Mathers Foundation. The research in the laboratory of W.G.J.H. was supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS) of the NIH under award numbers AI34501 and GM077418. S.T. received a doctoral fellowship from the Fonds Wetenschappelijk Onderzoek-Vlaanderen. S.G.F.R is supported by the Lundbeck Foundation.
The authors declare no competing financial interests.
Integrated supplementary information
For each primer, we specify the locus of hybridization on the cDNAs encoding the heavy chains of the conventional antibodies (isotype IgG1), on the cDNAs encoding the heavy chain only antibodies of isotype IgG3 or on the cDNAs encoding the heavy chain only antibodies of isotype IgG2. Arrows representing the primers are not drawn to scale. H: hinge; CH2: constant domain 2; CH3: constant domain 3; Fr1 (to 4): framework 1 (to 4); CDR1 (to 3): complementarity determining region 1 (to 3); VH: variable domain of the heavy chain of a conventional antibody (IgG1); VHH: variable domain of a heavy chain only antibody (IgG2 or IgG3). Immunoglobulin domains with highly conserved DNA sequences amongst camelid species (leader, CH2, CH3) are pattern filled. (A) Primers CALL001 and CAL002 to amplify the variable domains of all camelid immunoglobulin heavy chains from PBL cDNA (Step 21) are depicted in black. The primers VHH-Back and VHH-For to amplify the Nanobody repertoire via nested PCR (Step 24) are depicted with open arrows. (B) Van der linden et al. developed dedicated primers to separately amplify the IgG2 and IgG3 isotypes from llama glama49 (C) Maass et al. developed primers to separately amplify the IgG2 and IgG3 isotypes from llama pacos 50(D) Kastelic et al. developed a set of primers that amplify all VHs and VHHs from llama51.
A. Map of phage display vector pMES4 (4501bp, Genbank GQ907248). Nanobodies can be cloned as PstI-Eco91I fragments (Step 26) in between the pelB sequence (pelB) coding for the secretion signal peptide of PelB and a 6xHis-tag (His-tag) followed by the hemagglutinin tag (HA-tag) and gene III of filamentous phage fd (fd geneIII). Other annotations are the lac promotor/operator (Plac/operator), the gene conferring ampicillin resistance (AmpR), the bacterial origin of replication (rep) and the f1 origin of replication (f1ori). The annealing sites for the forward sequencing primer (MP57) and the backward primer (GIII) are also indicated on the map (used in Steps 30 and 68). B. Nucleotide sequence and amino acid sequence of the Nanobody cloning site. An amber stopcodon (TAG) is located downstream of the His-tag.
A. Map of phage display vector pMESy4 (4513bp; Genbank KF415192). Nanobodies can be cloned as PstI-Eco91I fragments (Step 26) in between the pelB sequence (pelB) coding for the secretion signal peptide of PelB and a 6xHis-tag (His-tag), followed by the CaptureSelectTM C-tag, the hemagglutinin tag (HA-tag) and gene III of filamentous phage fd (fd geneIII). Other annotations are the lac promotor/operator (Plac/operator), the gene conferring ampicillin resistance (AmpR), the bacterial origin of replication (rep) and the f1 origin of replication (f1ori). The annealing sites for the forward sequencing primer (MP57) and the backward primer (GIII) are also indicated on the map (used in Steps 30 and 68). B. Nucleotide sequence and amino acid sequence of the Nanobody cloning site. An amber stopcodon (TAG) is located downstream of the CaptureSelectTM C-tag.
About this article
Cite this article
Pardon, E., Laeremans, T., Triest, S. et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 9, 674–693 (2014). https://doi.org/10.1038/nprot.2014.039
This article is cited by
Studying the characteristics of nanobody CDR regions based on sequence analysis in combination with 3D structures
Journal of Genetic Engineering and Biotechnology (2022)
Fluids and Barriers of the CNS (2022)
Protein purification strategies must consider downstream applications and individual biological characteristics
Microbial Cell Factories (2022)
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
Communications Biology (2022)
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
Nature Cancer (2022)